Guangzhou Shunjian Biopharmaceutical Technology

Guangzhou Shunjian Biopharmaceutical Technology is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology. Founded to advance research originating from the Guangzhou Institutes of Biomedicine and Health, the company specialized in protein kinase inhibitors targeting resistant forms of cancer. Its lead candidate, olverembatinib (GZD824), is a potent third-generation BCR-ABL inhibitor designed to treat chronic myeloid leukemia, particularly in patients with the T315I mutation. In 2016, the company was acquired by Ascentage Pharma, which has since successfully brought the lead asset to market in China. Shunjian continues to operate as a subsidiary, contributing to the development of therapies for hematologic malignancies and solid tumors.